Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101
May 25, 2023 07:30 ET
|
Dyne Therapeutics, Inc.
- Initial Data from Global, Multiple Ascending Dose Phase 1/2 ACHIEVE Clinical Trial in Myotonic Dystrophy Type 1 Anticipated in the Second Half of 2023 - WALTHAM, Mass., May 25, 2023 (GLOBE...
Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting
May 17, 2023 07:30 ET
|
Dyne Therapeutics, Inc.
- Broad Distribution in CNS Demonstrated in Non-Human Primates - - Achieved Reduction of Toxic Nuclear DMPK RNA and Foci in the Brain in a DM1 Disease Model - WALTHAM, Mass., May 17, 2023 (GLOBE...
Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
May 11, 2023 07:30 ET
|
Dyne Therapeutics, Inc.
- On Track to Report Initial Data from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD During the Second Half of 2023 - WALTHAM, Mass., May 11, 2023 (GLOBE...
Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference
May 03, 2023 07:35 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS
May 02, 2023 16:46 ET
|
Dyne Therapeutics, Inc.
- FORCE Delivers to CNS in Non-Human Primates -- FORCE Achieves Robust Reduction of Toxic Nuclear DMPK RNA and Foci in Brain of a DM1 Disease Model - WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE)...
Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
March 23, 2023 07:30 ET
|
Dyne Therapeutics, Inc.
- Data from the Global, Multiple Ascending Dose Phase 1/2 DELIVER Clinical Trial Anticipated in the Second Half of 2023 - WALTHAM, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc....
Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference
March 20, 2023 07:30 ET
|
Dyne Therapeutics, Inc.
- Company Presents Overviews of ACHIEVE and DELIVER Global Clinical Trials with Data Anticipated from Both Studies in the Second Half of 2023 - - FORCE™ Platform Achieves Robust Exon Skipping,...
Dyne Therapeutics to Present at Upcoming Investor Conferences
March 07, 2023 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...
Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
March 02, 2023 07:30 ET
|
Dyne Therapeutics, Inc.
- Data Anticipated in the Second Half of 2023 from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD - WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Dyne...
Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for...